Amgen Highlights Data To Be Presented At 21st Congress Of The European Hematology Association
BLINCYTO® (Blinatumomab) TOWER Study Demonstrates Improved Overall Survival Versus Standard of Care in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia
TOWER Study to be Presented at Presidential Symposium as a Best Abstract
Sub-group Analyses From Pivotal Head-To-Head Phase 3 Studies Provide Further Insight Into Kyprolis® (Carfilzomib) as Treatment Option for Patients With Multiple Myeloma
Aranesp® (Darbepoetin Alfa) Phase 3 ARCADE Data Demonstrates Significant Reduction in Red Blood Cell Transfusions in Anemic Patients With Myelodysplastic Syndrome
THOUSAND OAKS, Calif., May 19, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced it will present new data from it...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Anemia | Aranesp | Hematology | Leukemia | Myelodysplastic Syndrome | Myeloma | Pharmaceuticals | Politics | Study